Interleukin-6 May Contribute to Mortality in Parkinson's Disease Patients: A 4-Year Prospective Study. (16th August 2015)

• Record Type: Journal Article
• Authors: Dufek, Michal; Rektorova, Irena; Thon, Vojtech; Lokaj, Jindrich; Rektor, Ivan
• Other Names: Hagell Peter Academic Editor.
• Is Part Of: Parkinson's disease. Volume 2015(2015)
• Publication Date: 2015-08-16
• Subjects: Parkinson's disease -- Periodicals; Parkinson's disease -- Treatment -- Periodicals; 616.833005
• DOI: 10.1155/2015/898192
• Languages: English
• ISSNs: 2090-8083

Abstract

Abstract : Objectives . The association between abnormal serum immunomarkers and mortality in 53 consecutive Parkinson's disease patients was studied. Materials and Methods . The plasma level of specific inflammatory cytokines was investigated: mannan-binding lectin (MBL), interleukin- (IL-) 6, and tumor necrosis factor-alpha (TNF- α ). The baseline serum immunomarkers obtained from patients who died (n = 16 ) during a four-year follow-up period were compared with the data of patients who survived (n = 37 ). Results . The baseline level of IL-6 was significantly higher in the deceased patients than in the survivors. Elevated IL-6 levels and age were major independent contributors to disease mortality. Differences between other plasma cytokine level abnormalities were not significant. Conclusion . This study showed that IL-6 elevation may be a marker of increased mortality risk in Parkinson's disease patients. The inflammation may act in association with other factors and comorbidities in progressive neurodegenerative pathology.